Hooker, Deborah S. http://orcid.org/0000-0002-5468-0967
Grabe-Heyne, Kristin
Henne, Christof
Bader, Peter http://orcid.org/0000-0003-4554-0265
Toumi, Mondher http://orcid.org/0000-0001-7939-7204
Furniss, Stephen J.
Article History
Accepted: 28 September 2021
First Online: 16 October 2021
Declarations
:
: The preparation of this article was supported by Medac GmbH, Germany.
: Kristin Grabe-Heyne and Christof Henne are both employees of Medac GmbH, a company working in the field of allogeneic HSCT. Deborah Hooker and Jim Furniss are independent market access consultants who were supported by Medac GmbH for the preparation of this article and other work. They provide consulting to many different pharmaceutical companies. Peter Bader was not funded by Medac for this article. He declares grants received from Medac, Novii and Riemser and consulting fees or honorarium from Amgen, Jazz, Medac, Novartis, and Riemser, and payment for lectures including service on speakers bureaus from Novartis. PB is a patent holder of chemical grade mesenchymal stem cells and receives royalties from Medac. Mondher Toumi was not funded by Medac for this article. He has no conflicts of interest to declare.
: Not applicable.
: Not applicable.
: DH performed the literature search, wrote the draft manuscript, edited the draft manuscript and approved the final version. KG-H, CH, PB, MT and JF critically examined the published data, edited the draft manuscript and approved the final version.
: Not applicable.
: Not applicable.
: Not applicable.
: Data sharing is not applicable to this article as no datasets were generated or analysed.